Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury
NCT ID: NCT00980915
Last Updated: 2021-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6600 participants
OBSERVATIONAL
2008-12-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim 1- To validate the prediction model (Lung Injury Prediction Score) in a population based sample of hospitalized patients.
Aim 2- To determine the significance of health-care related ALI risk modifiers in a population based sample.
Aim 3- To compare the short and long term outcomes between patients at high risk who do, and do not develop ALI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lung Injury Prediction Study
NCT00889772
Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease
NCT00217880
Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials
NCT00719446
Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai
NCT01186874
Pulmonary Microbiota and ARDS Mortality
NCT04133558
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical prediction models have been extensively used in the clinical practice to identify patients at high risks who may benefit from specific interventions. However, no such tool exists to predict the development of ALI in patients at risk. We have recently developed an ALI prediction model (Lung Injury Prediction Score:LIPS)which incorporates demographic, environmental and clinical characteristics at the time of, and before, hospital admission. If validated, this model will serve to find the population of patients at high risk of ALI in whom future prevention trials will be conducted. By determining not only patients at high risk but also the attributable burden of ALI/ARDS in contemporary cohorts of patients at risk, our findings will facilitate the prioritization of preventive strategies and future clinical trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
At risk for Acute Lung Injury
Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI
Cases-High risk patients that do develop Acute Lung Injury
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Acute lung injury or pulmonary edema already present at the time of hospital admission
* Admitted for comfort or hospice care only
* Children
* Hospital readmission
* Patients admitted for cardiac telemetry, coronary care unit, low risk elective surgeries, labor and delivery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ognjen Gajic
Ognjen Gajic, M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ognjen Gajic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIPSSTUDY
Identifier Type: -
Identifier Source: secondary_id
08-003560
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.